350 related articles for article (PubMed ID: 28756619)
1. Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?
Prendeville S; Al-Bozom I; Compérat E; Sweet J; Evans AJ; Ben-Gashir M; Mete O; van der Kwast TH; Downes MR
Histopathology; 2017 Dec; 71(6):926-933. PubMed ID: 28756619
[TBL] [Abstract][Full Text] [Related]
2. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer.
Evans AJ; Humphrey PA; Belani J; van der Kwast TH; Srigley JR
Am J Surg Pathol; 2006 Jun; 30(6):684-93. PubMed ID: 16723845
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
4. Expression of neuroendocrine markers in non-neuroendocrine endometrial carcinomas.
Moritz AW; Schlumbrecht MP; Nadji M; Pinto A
Pathology; 2019 Jun; 51(4):369-374. PubMed ID: 31040050
[TBL] [Abstract][Full Text] [Related]
5. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series.
Gopalan A; Al-Ahmadie H; Chen YB; Sarungbam J; Sirintrapun SJ; Tickoo SK; Reuter VE; Fine SW
Histopathology; 2022 Aug; 81(2):246-254. PubMed ID: 35758203
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
Yuan TC; Veeramani S; Lin FF; Kondrikou D; Zelivianski S; Igawa T; Karan D; Batra SK; Lin MF
Endocr Relat Cancer; 2006 Mar; 13(1):151-67. PubMed ID: 16601285
[TBL] [Abstract][Full Text] [Related]
8. De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome.
Abdulfatah E; Reichert ZR; Davenport MS; Chinnaiyan AM; Dadhania V; Wang X; Mannan R; Kunju LP; Hollenbeck BK; Montgomery JS; Kaffenberger SD; Morgan TM; Alva AS; Palapattu GS; Vaishampayan UN; Alumkal JJ; Spratt DE; Udager AM; Mehra R
Med Oncol; 2021 Feb; 38(3):26. PubMed ID: 33586037
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine differentiation in breast carcinoma: clinicopathological features and outcome.
Bogina G; Munari E; Brunelli M; Bortesi L; Marconi M; Sommaggio M; Lunardi G; Gori S; Massocco A; Pegoraro MC; Zamboni G
Histopathology; 2016 Feb; 68(3):422-32. PubMed ID: 26114478
[TBL] [Abstract][Full Text] [Related]
10. Primary breast carcinomas with neuroendocrine features: Clinicopathological features and analysis of tumor growth patterns in 36 cases.
Kelten Talu C; Leblebici C; Kilicaslan Ozturk T; Hacihasanoglu E; Baykal Koca S; Gucin Z
Ann Diagn Pathol; 2018 Jun; 34():122-130. PubMed ID: 29661717
[TBL] [Abstract][Full Text] [Related]
11. [Clinicopathologic features of primary renal neuroendocrine carcinoma].
Wang XH; Lu X; He B; Jiang YX; Yu WJ; Wang H; Zhang W; Li YJ
Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):851-856. PubMed ID: 30423609
[No Abstract] [Full Text] [Related]
12. Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer.
Montironi R; Cimadamore A; Lopez-Beltran A; Scarpelli M; Aurilio G; Santoni M; Massari F; Cheng L
Cells; 2020 Apr; 9(5):. PubMed ID: 32344931
[TBL] [Abstract][Full Text] [Related]
13. Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis.
Helpap B; Köllermann J
Virchows Arch; 1999 May; 434(5):385-91. PubMed ID: 10389621
[TBL] [Abstract][Full Text] [Related]
14. Clinical, pathologic, and molecular features of amphicrine prostate cancer.
Graham LS; Haffner MC; Sayar E; Gawne A; Schweizer MT; Pritchard CC; Coleman I; Nelson PS; Yu EY
Prostate; 2023 May; 83(7):641-648. PubMed ID: 36779357
[TBL] [Abstract][Full Text] [Related]
15. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma.
Aprikian AG; Cordon-Cardo C; Fair WR; Reuter VE
Cancer; 1993 Jun; 71(12):3952-65. PubMed ID: 7685237
[TBL] [Abstract][Full Text] [Related]
16. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z
Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma.
Downes MR; Torlakovic EE; Aldaoud N; Zlotta AR; Evans AJ; van der Kwast TH
J Clin Pathol; 2013 Sep; 66(9):779-86. PubMed ID: 23775437
[TBL] [Abstract][Full Text] [Related]
18. Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites.
Roy M; Buehler DG; Zhang R; Schwalbe ML; Baus RM; Salamat MS; Lloyd RV; Rosenbaum JN
Endocr Pathol; 2019 Mar; 30(1):35-42. PubMed ID: 30523500
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
Xiao GQ; Ho G; Suen C; Hurth KM
Prostate; 2021 Jun; 81(8):469-477. PubMed ID: 33848377
[TBL] [Abstract][Full Text] [Related]
20. Human ASH1 expression in prostate cancer with neuroendocrine differentiation.
Rapa I; Ceppi P; Bollito E; Rosas R; Cappia S; Bacillo E; Porpiglia F; Berruti A; Papotti M; Volante M
Mod Pathol; 2008 Jun; 21(6):700-7. PubMed ID: 18311112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]